Department of Medicine

Pittsburgh Lends Expertise, Arms to Moderna Vaccine Development
On Monday, Moderna became the second company to announce promising early results of its Phase 3 COVID-19 vaccine trial. The Pittsburgh site, led by Pitt’s Judy Martin, has seen more than 250 Pittsburghers roll up their sleeves to volunteer.
A depiction of the coronavirus
Four Pitt experts offer their thoughts on Pfizer’s announcement today of a vaccine that early data show is more than 90% effective in preventing COVID-19.
A man in a gray-brown jacket and a light collared shirt and dark tie
At Pitt, the MiGEL Lab and its robot liquid handler play a major role in processing surveillance testing samples. Learn how samples are pooled, tested and sequenced to help in the battle against COVID-19.
A depiction of a bloodstream and a virus
The National Institutes of Health has selected Pitt to lead a trio of Phase 3 clinical trials involving COVID-19 patients that will explore the use of blood thinners in saving lives and improving care.
A network of groups of people connected by lines
Contact tracing has been underway at Pitt for months to help prevent the spread of COVID-19. To make it effective, the entire Pitt community is being asked to follow certain procedures when any of its members test positive or experience symptoms.